GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

PHOENIX — Arizona is suing a major drug maker, accusing it of gaming the system by simply renaming an asthma drug to increase ...

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline.It ...

In a report released on February 5, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with ...

The attorney general is accusing GlaxoSmithKline of allegedly violating the Arizona Consumer Fraud Act. PHOENIX — Arizona ...

The state’s top lawyer accused a British multinational drug company of “deceptive and unfair practices” that endangered lives and exploited American taxpayers.

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

Ms. Mayes is seeking a declaration that the company violated the Arizona Consumer Fraud Act, which prohibits companies from selling a new drug at artificially inflated prices, and maximum statutory ...

Spandana Sphoorty Financial Ltd, Reliance Power Ltd, Fusion Finance Ltd and Aarti Pharmalabs Ltd are among the other gainers in the BSE's 'A' group today, 06 February 2025.

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was up ...